-
Fierce Biotech2 weeks ago
Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
Novartis is investing more than 3.3 billion Chinese yuan (roughly $480 million) to soup up its manufacturing facility in Beijing and strengthen its R&D campus in...
-
Fierce Biotech2 weeks ago
Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double...
-
Fierce Biotech2 weeks ago
FDA solicits feedback on controversial national priority voucher review pathway
The FDA has scheduled a public hearing for June 12 to hear input on the Commissioner’s National Priority Voucher program, which it introduced last June. So...
-
Fierce Biotech2 weeks ago
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
Sanofi has returned to T-cell engager territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali...
-
Fierce Biotech2 weeks ago
Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the...
-
Fierce Biotech2 weeks ago
NIH grant cuts hit women, early-career scientists the hardest: analysis
Last year’s funding cuts at the National Institutes of Health disproportionately impacted women and early-career researchers, according to a new analysis, raising questions about what the...
-
Fierce Biotech3 weeks ago
Oryon shines out of stealth with $21M to fight Parkinson’s disease
When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. The...
-
Fierce Biotech3 weeks ago
Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial
Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule...
-
Fierce Biotech3 weeks ago
Behind the curtain: What Xaira is building after its $1B fundraise
What has Xaira been doing since its $1 billion raise? Xaira COO Jeff Jonker joins “The Top Line” to talk strategy, AI and the company’s long-game...
-
Fierce Biotech3 weeks ago
Intuitive recalls surgical stapler reloads following patient death
This comes in the same week that Intuitive reported a cyberattack, with a phishing incident targeting some of its employees.
Terns rebuffed a higher bid before selling to Merck
